5722-94-1

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dimethoxy-2-methylbenzoic acid is used as a synthetic intermediate for the production of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the synthesis of a wide range of drugs, contributing to the development of novel therapeutic agents.
Used in Chemical Synthesis:
In the field of organic chemistry, 3,4-dimethoxy-2-methylbenzoic acid is used as a synthetic intermediate for the preparation of various organic compounds. Its reactivity and functional groups make it a valuable building block for the synthesis of complex molecules, including natural products, agrochemicals, and other specialty chemicals.
Used in the Synthesis of 5,5''-didesisopropyl-5,5''-dialkylapogossypol Derivatives:
3,4-Dimethoxy-2-methylbenzoic acid is specifically used as a synthetic intermediate for the synthesis of 5,5''-didesisopropyl-5,5''-dialkylapogossypol derivatives. These derivatives are of interest due to their potential applications in various fields, including pharmaceuticals and materials science. The unique structure of 3,4-dimethoxy-2-methylbenzoic acid enables the efficient synthesis of these derivatives, expanding the scope of their potential applications.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 25, p. 263, 1982 DOI: 10.1021/jm00345a013The Journal of Organic Chemistry, 33, p. 494, 1968 DOI: 10.1021/jo01266a004

Upstream product

• 67-64-1 acetone 
• 5417-20-9 2-methyl-3,4-dimethoxyacetophenone 
• 77-78-1 dimethyl sulfate 
• 124-38-9 carbon dioxide 
• 74866-17-4 3,4-dimethoxy-2-methyl-1-bromobenzene 
• 67489-09-2 lithium 3,4-dimethoxybenzoate 
• 74-88-4 methyl iodide 
• 293731-03-0 (3,4-dimethoxy-2-methyl-phenyl)-oxo-acetic acid ethyl ester 
• 93-07-2 Veratric acid 
• 598-30-1 sec.-butyllithium 
• 4463-33-6 1,2-dimethoxy-3-methylbenzene 
• 10028-15-6 ozone 
• 141-78-6 ethyl acetate 
• 7732-18-5 water 

Downstream Products

• 518-90-1 3,4-dimethoxy-phthalic acid 
• 80547-78-0 2-methyl-3,4-dimethoxybenzyl alcohol 
• 15364-84-8 Ethyl 3,4-dimethoxy-2-methyl benzoate 
• 740799-82-0 3,4-dihydroxy-2-methyl benzoic acid methyl ester 
• 1338708-45-4 3,4-bis((4-methoxybenzyl)oxy)-2-methyl-N-(2-(pyrrolidin-1-yl)ethyl)benzamide 
• 1338708-44-3 C₂₄H₂₄O₆ 
• 1338708-43-2 C₂₅H₂₆O₆ 
• 1338708-53-4 C₃₂H₃₈N₂O₅ 
• 1597710-76-3 1,4-dioxan-2-yl 3,4-dimethoxy-2-methylbenzoate 
• 51234-09-4 2-methyl-3,4-dimethoxybenzaldehyde 
• 15365-32-9 N-Benzyl-N-(2-carbaethoxy-5,6-dimethoxybenzyl)-glycinaethylester 
• 15365-27-2 Ethyl 2-bromomethyl-3,4-dimethoxybenzoate 
• 80547-82-6 2-methyl-3,4-dimethoxy-6-nitro-β-nitrostyrene 
• 80547-81-5 2-methyl-3,4-dimethoxy-β-nitrostyrene 

Relevant academic research and scientific papers

NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF

The present invention relates to novel dioxoisoquinolinone derivative compounds and use thereof. More specifically, the present invention relates to novel dioxoisoquinolinone derivative compounds with inhibition activity of EZH1(Enhancer of zeste homolog 1) and/or EZH2(Enhancer of zeste homolog 2) activity, a pharmaceutically acceptable salt thereof, and/or pharmaceutical compositions comprising the same.

NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME

The present disclosure relates to novel heterotricyclic derivative compounds and the use thereof, and more particularly, to novel heterotricyclic derivative compounds having inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2 (enhancer of zeste homolog 2) activity, pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing these compounds.

Evidence for a trianion intermediate in the metalation of 4-hydroxy-6,7-dimethoxy-8-methyl-2-naphthoic acid. methodology and application to racemic 5,5′-didesisopropyl-5,5′-dialkylapogossypol derivatives

The metalation of 4-hydroxy-6,7-dimethoxy-8-methyl-2-naphthoic acid (8) affording trianion 6 is presented and applied to the regioselective efficient construction of a series of 5,5′-didesisopropyl-5,5′- dialkylapogossypol derivatives 3 that are potent pa

DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS

Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof.

TROPANE COMPOUNDS

A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

Competition of substituents for ortho direction of metalation of veratric acid

LTMP (5 equiv) metalates randomly veratric acid (1). Under external quench conditions, the thermodynamically more stable lithium 2-lithio-3,4-dimethoxybenzoate (2) reacts with a variety of electrophiles to give versatile building units that are not easily accessible by conventional means. Under in situ quench conditions (LTMP/TMSCl), a reversal of regioselectivity is observed and 6-trimethylsilyl-3,4-dimethoxybenzoic acid (10) is formed predominantly.

A practical synthesis of 3,4-dimethoxy-o-toluic acid

A streamlined, telescoped process has been developed for the preparation of 3,4-dimethoxy-o-toluic acid, starting with economical and readily available 2,3-dimethoxybenzaldehyde. Catalytic reduction of the aldehyde functional group generated dimethoxytolu

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Catechol O-methyltransferase. 12. Affinity Labeling the Active Site with the Oxidation Products of 5,6-Dihydroxyindole

5,6-Dihydroxyindole (5,6-DHI) and a series of 4- and/or 7-methylated analogues of 5,6-DHI have been synthesized and evaluated for their ability to inactivate purified liver rat catechol O-methyltransferase (COMT).The inactivation of COMT by these agents could be prevented by excluding oxygen from the incubation mixtures, indicating the necessity for their oxidation to the corresponding aminochromes.Substrate protection studies and kinetic studies suggested that the loss of enzyme activity resulted from the modification of a crucial amino acid residue at the active site of COMT through reaction with the quinoid oxidation products.The COMT inhibitory activity of the 4- and/or 7-methylazed analogues of 5,6-DHI argue against a mechanism involving a 1,4 Michael addition reaction at positions 4 or 7 on the aminochrome.Cnsidering the number of potential eletrophilic centers on the basic aminochrome structure, the site of the reaction might change depending on the aromatic substitution pattern.The preferred pathway of reaction may be determined in part by the juxtaposition of the protein nucleophile to the possible sites of attack on the electrophilic ligand but also in part on the reactivity of the electrophilic site which might change with substitution on the aromatic ring.